weight loss 2 posts

• Not Apples to Apples: How Shifting Trial Criteria Distort GLP-1 Weight-Loss Headlines
  15 May 2026  ·  pharma LLY Novo Nordisk NVO Eli Lilly
  The headline weight-loss percentages from liraglutide, semaglutide, and tirzepatide trials look like a straight-line march of progress. They are not. Inclusion criteria have shifted systematically over a decade, changing who gets enrolled and for how long - making cross-trial comparisons unreliable without a head-to-head.
• The Obesity Drug Chessboard after ADA2025 with Q2 Earnings in Play ♟️
  21 July 2025  ·  Eli Lilly LLY Novo Nordisk NOVO-B.CO NVO
  Quick status check on Novo, Lilly, and rivals after ADA 2025 - just ahead of Q2 earnings.